Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects

•An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument...

Full description

Saved in:
Bibliographic Details
Published inClinica chimica acta Vol. 522; pp. 144 - 151
Main Authors Ferrari, Davide, Clementi, Nicola, Spanò, Sestina Maria, Albitar-Nehme, Sami, Ranno, Stefania, Colombini, Alessandra, Criscuolo, Elena, Di Resta, Chiara, Tomaiuolo, Rossella, Viganó, Marco, Mancini, Nicasio, De Vecchi, Elena, Locatelli, Massimo, Mangia, Alessandra, Perno, Carlo Federico, Banfi, Giuseppe
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.11.2021
Subjects
Online AccessGet full text
ISSN0009-8981
1873-3492
1873-3492
DOI10.1016/j.cca.2021.08.024

Cover

Abstract •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument conversion factors is not sufficient to harmonize different instruments readouts from single samples.•The devices tested performed well in predicting neutralization activity based on the antibody titer. Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS. Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers. The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer. A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.
AbstractList •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument conversion factors is not sufficient to harmonize different instruments readouts from single samples.•The devices tested performed well in predicting neutralization activity based on the antibody titer. Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS. Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers. The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer. A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.
Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.BACKGROUND AND AIMSVaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.MATERIALS AND METHODSSera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.RESULTSThe WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.CONCLUSIONSA reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.
Author Criscuolo, Elena
Di Resta, Chiara
Perno, Carlo Federico
Spanò, Sestina Maria
Mancini, Nicasio
Ferrari, Davide
Tomaiuolo, Rossella
Banfi, Giuseppe
Viganó, Marco
Locatelli, Massimo
Albitar-Nehme, Sami
Clementi, Nicola
Ranno, Stefania
Colombini, Alessandra
Mangia, Alessandra
De Vecchi, Elena
Author_xml – sequence: 1
  givenname: Davide
  surname: Ferrari
  fullname: Ferrari, Davide
  email: davide.ferrari@unipr.it
  organization: SCVSA Department, University of Parma, 43121 Parma, Italy
– sequence: 2
  givenname: Nicola
  surname: Clementi
  fullname: Clementi, Nicola
  organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy
– sequence: 3
  givenname: Sestina Maria
  surname: Spanò
  fullname: Spanò, Sestina Maria
  organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy
– sequence: 4
  givenname: Sami
  surname: Albitar-Nehme
  fullname: Albitar-Nehme, Sami
  organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
– sequence: 5
  givenname: Stefania
  surname: Ranno
  fullname: Ranno, Stefania
  organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
– sequence: 6
  givenname: Alessandra
  surname: Colombini
  fullname: Colombini, Alessandra
  organization: IRCCS Orthopedic Institute Galeazzi, Laboratorio di Biotecnologie Applicate all'Ortopedia, Milan, Italy
– sequence: 7
  givenname: Elena
  surname: Criscuolo
  fullname: Criscuolo, Elena
  organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy
– sequence: 8
  givenname: Chiara
  surname: Di Resta
  fullname: Di Resta, Chiara
  organization: IRCCS Ospedale San Raffaele, 20158 Milan, Italy
– sequence: 9
  givenname: Rossella
  surname: Tomaiuolo
  fullname: Tomaiuolo, Rossella
  organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy
– sequence: 10
  givenname: Marco
  surname: Viganó
  fullname: Viganó, Marco
  organization: IRCCS Orthopedic Institute Galeazzi, Laboratorio di Biotecnologie Applicate all'Ortopedia, Milan, Italy
– sequence: 11
  givenname: Nicasio
  surname: Mancini
  fullname: Mancini, Nicasio
  organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy
– sequence: 12
  givenname: Elena
  surname: De Vecchi
  fullname: De Vecchi, Elena
  organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy
– sequence: 13
  givenname: Massimo
  surname: Locatelli
  fullname: Locatelli, Massimo
  organization: IRCCS Ospedale San Raffaele, 20158 Milan, Italy
– sequence: 14
  givenname: Alessandra
  surname: Mangia
  fullname: Mangia, Alessandra
  organization: Liver Unit, Department of Medical Sciences, IRCCS Fondazione, “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, Italy
– sequence: 15
  givenname: Carlo Federico
  surname: Perno
  fullname: Perno, Carlo Federico
  organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
– sequence: 16
  givenname: Giuseppe
  surname: Banfi
  fullname: Banfi, Giuseppe
  organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy
BookMark eNp9kU1r3DAQhkVJaTZpf0BvPvZiRyPLXxQKYUmTQqDQfFzFWB5ttXilRLKXpr--cjYU2kPQYZBmnlfD-56wI-cdMfYReAEc6rNtoTUWggsoeFtwId-wFbRNmZeyE0dsxTnv8rZr4ZidxLhNV8lreMeOSylFBbxaMbzCsPPO_sbJepd5k0X7K3uc0U12Sm97ym7Of9zka3-fiyxS8KPfWI1jhjHiU8zmaN1maeAC71Fr63CiIYtzvyU9xffsrcEx0oeXesruvl7crq_y6--X39bn17mWop3ypgKUfQ2mqTlVGrgRNYiyNelUQLo3ZIaBS4Km6crByKHTiAb7voJK9Lo8ZV8Oug9zv6NBk5sCjuoh2B2GJ-XRqn87zv5UG79Xbdm0vK6SwKcXgeAfZ4qT2tmoaRzRkZ-jElUtoQSo6zQKh1EdfIyBzN9vgKslGrVVKRq1RKN4q1I0iWn-Y_Szw37Zxo6vkp8PJCX79paCitqS0zTYkBxWg7ev0H8ACnerzA
CitedBy_id crossref_primary_10_5858_arpa_2021_0604_SA
crossref_primary_10_1080_21645515_2023_2215677
crossref_primary_10_3390_vaccines9111357
crossref_primary_10_3390_v14020312
crossref_primary_10_1016_j_cca_2021_09_022
crossref_primary_10_3390_s22145463
crossref_primary_10_1128_spectrum_05353_22
crossref_primary_10_3389_fpubh_2022_847384
crossref_primary_10_3390_vaccines11081380
crossref_primary_10_1002_bimj_202400027
crossref_primary_10_1097_FTD_0000000000000945
crossref_primary_10_1515_cclm_2023_0353
crossref_primary_10_1002_rmv_2451
crossref_primary_10_3389_fimmu_2022_1002576
crossref_primary_10_3390_biomedicines10112892
crossref_primary_10_1111_vox_13480
crossref_primary_10_1515_cclm_2022_0262
crossref_primary_10_1128_spectrum_00597_22
crossref_primary_10_1515_cclm_2022_1161
crossref_primary_10_1002_jcla_24363
crossref_primary_10_3390_vaccines9101092
crossref_primary_10_1016_j_ijid_2022_05_061
crossref_primary_10_7554_eLife_72500
crossref_primary_10_1002_jcla_24306
crossref_primary_10_1016_j_clinbiochem_2023_110681
Cites_doi 10.1111/j.0006-341X.2000.01134.x
10.1093/clinchem/hvab039
10.3390/vaccines9050522
10.1016/j.jcv.2020.104544
10.1093/infdis/jiaa659
10.1016/j.forsciint.2018.04.038
10.1001/jama.2021.3341
10.2217/fvl-2017-0003
10.1016/j.vaccine.2021.06.020
10.1016/S0140-6736(21)00502-X
10.1016/S0140-6736(21)00501-8
10.1056/NEJMc2101667
10.1515/cclm-2021-0023
10.1128/JCM.02511-20
10.1016/j.ebiom.2020.103101
10.1016/j.ijid.2020.12.003
10.1177/000456329703400317
10.1016/j.clim.2020.108634
10.1038/d41573-020-00151-8
ContentType Journal Article
Copyright 2021 Elsevier B.V.
Copyright © 2021 Elsevier B.V. All rights reserved.
2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.
Copyright_xml – notice: 2021 Elsevier B.V.
– notice: Copyright © 2021 Elsevier B.V. All rights reserved.
– notice: 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.
DBID AAYXX
CITATION
7X8
5PM
DOI 10.1016/j.cca.2021.08.024
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1873-3492
EndPage 151
ExternalDocumentID PMC8378065
10_1016_j_cca_2021_08_024
S0009898121003028
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29B
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
G8K
GBLVA
HLW
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LCYCR
LX3
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
RNS
ROL
RPZ
SBG
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
WH7
WUQ
X7M
XPP
ZA5
ZGI
~02
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABDPE
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
~HD
7X8
ACLOT
5PM
ID FETCH-LOGICAL-c428t-751a4b61f760e5c10f261238f8f851ecbfefdd04e17793df4d9caafabb5152bc3
IEDL.DBID AIKHN
ISSN 0009-8981
1873-3492
IngestDate Thu Aug 21 18:11:17 EDT 2025
Sun Sep 28 07:57:32 EDT 2025
Thu Sep 18 00:04:39 EDT 2025
Thu Apr 24 22:55:09 EDT 2025
Fri Feb 23 02:39:45 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
SARS-CoV-2
Serological standard
Comirnaty vaccine
WHO
Neutralization
Language English
License Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c428t-751a4b61f760e5c10f261238f8f851ecbfefdd04e17793df4d9caafabb5152bc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8378065
PMID 34425105
PQID 2564131166
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8378065
proquest_miscellaneous_2564131166
crossref_primary_10_1016_j_cca_2021_08_024
crossref_citationtrail_10_1016_j_cca_2021_08_024
elsevier_sciencedirect_doi_10_1016_j_cca_2021_08_024
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationTitle Clinica chimica acta
PublicationYear 2021
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Worldometers, COVID-19 statistics.
Manisty, Otter, Treibel, McKnight, Altmann, Brooks, Noursadeghi, Boyton, Semper, Moon (b0030) 2021; 397
F. Muecksch, H. Wise, B. Batchelor, M. Squires, E. Semple, C. Richardson, J. McGuire, S. Clearly, E. Furrie, N. Greig, G. Hay, K. Templeton, J.C.C. Lorenzi, T. Hatziioannou, S. Jenks, P.D. Bieniasz, Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients, J. Infect. Dis. 223 (2020) 389–398. doi:10.1093/infdis/jiaa659.
Izda, Jeffries, Sawalha (b0010) 2021; 222
F. Krammer, K. Srivastava, P. Team, V. Simon, H. Alshammary, A. Amoako, M. Awawda, K. Beach, C.M. 1 3 Bermúdez-González, D. Bialak, J.M. Carreño, R. Chernet, L. Eaker, E. Ferreri, D. Floda, C. Gleason, J. Hamburger, K. Jiang, G.D. Kleiner, J. Jurczyszak, W. Matthews, L. Mendez, I. Mulder, A. Nabeel, K. Raskin, A. Russo, M. Salimbangon, A. Saksena, G. Shin, L. Singh, D. Sominsky, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. 384 (2021) 1372-1374. doi: 10.1056/NEJMc2101667.
Ferrari, Manca, Premaschi, Banfi, Locatelli (b0105) 2018; 288
C. Di Resta, D. Ferrari, M. Viganò, M. Moro, E. Sabetta, M. Minerva, A. Ambrosio, M. Locatelli, R. Tomaiuolo, The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects, Vaccines. May 18 (2021) 522. doi:10.3390/vaccines9050522.
Le, Cramer, Chen, Mayhew (b0015) 2020; 19
M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L. Lightstone, X.-N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, M. Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine., Lancet (London, England). 6736 (2021) 10–12. doi:10.1016/S0140-6736(21)00502-X.
Ferrari, Di Resta, Tomaiuolo, Sabetta, Pontillo, Motta, Locatelli (b0100) 2021; 39
WHO, Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody, 2020.
Bonelli, Blocki, Bunnell, Chu, Arriel De La, Grenache, Marzucchi, Montomoli, Okoye, Pallavicini, Streva, Torelli, Wagner, Zanin, Zierold, Wassenberg (b0055) 2021; 49
Schnurra, Reiners, Biemann, Kaiser, Trawinski, Jassoy (b0065) 2020; 129
2008 (accessed 10 July 2021).
Padoan, Bonfante, Pagliari, Bortolami, Negrini, Zuin, Bozzato, Cosma, Sciacovelli, Plebani (b0070) 2020; 62
Centers for Disease Control and Prevention (US), SARS-CoV-2 Variants of Concern, Centers Dis. Control Prev. (2021). https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern%0Ahttps://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html. (accessed 12 June 2021).
Venkatraman (b0115) 2000; 56
C. Therrien, B. Serhir, M. Bélanger-Collard, J. Skrzypczak, D.K. Shank, C. Renaud, J. Girouard, V. Loungnarath, M. Carrier, G. Brochu, F. Tourangeau, B. Gilfix, A. Piche, R. Bazin, R. Guérin, M. Lavoie, V. Martel-Laferrière, C. Fortin, A. Benoit, D. Marcoux, N. Gauthier, A.M. Laumaea, R. Gasser, A. Finzi, M. Roger, Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories, J. Clin. Microbiol. 59 (2021). doi:10.1128/JCM.02511-20.
Tang, Farnsworth (b0060) 2021; 67
2020 (accessed 10 February 2021).
S. Saadat, Z.T. Rikhtegaran, L. James, N. Michelle, F. Matthew B., A.D. Harris, M.M. Sajadi, Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health CareWorkers Previously InfectedWith SARS-CoV-2, JAMA - J. Am. Med. Assoc. Mar 1;e213 (2021). doi:10.1001/jama.2021.3341.
Kittel, Muth, Zahn, Roth, Thiaucourt, Gerhards, Haselmann, Neumaier, Findeisen (b0050) 2021; 103
World Health Organization, WHO TRS: Recommendations for the preparation, characterization and establishment of international and other biological reference standards, http://www.who.int/immunization_standards/vaccine_reference_preparations/TRS932Annex 2_Inter _biol ef standards rev2004.pdf?ua=1, 2006 (accessed 12 March 2021).
Page, Wilkinson, Mattiuzzo, Efstathiou, Minor (b0085) 2017; 12
Payne (b0110) 1997; 34
10.1016/j.cca.2021.08.024_b0005
Schnurra (10.1016/j.cca.2021.08.024_b0065) 2020; 129
Ferrari (10.1016/j.cca.2021.08.024_b0105) 2018; 288
Le (10.1016/j.cca.2021.08.024_b0015) 2020; 19
10.1016/j.cca.2021.08.024_b0020
10.1016/j.cca.2021.08.024_b0075
Tang (10.1016/j.cca.2021.08.024_b0060) 2021; 67
10.1016/j.cca.2021.08.024_b0035
Bonelli (10.1016/j.cca.2021.08.024_b0055) 2021; 49
Venkatraman (10.1016/j.cca.2021.08.024_b0115) 2000; 56
10.1016/j.cca.2021.08.024_b0045
Manisty (10.1016/j.cca.2021.08.024_b0030) 2021; 397
10.1016/j.cca.2021.08.024_b0025
Payne (10.1016/j.cca.2021.08.024_b0110) 1997; 34
10.1016/j.cca.2021.08.024_b0080
10.1016/j.cca.2021.08.024_b0090
Ferrari (10.1016/j.cca.2021.08.024_b0100) 2021; 39
Izda (10.1016/j.cca.2021.08.024_b0010) 2021; 222
10.1016/j.cca.2021.08.024_b0040
10.1016/j.cca.2021.08.024_b0095
Padoan (10.1016/j.cca.2021.08.024_b0070) 2020; 62
Page (10.1016/j.cca.2021.08.024_b0085) 2017; 12
Kittel (10.1016/j.cca.2021.08.024_b0050) 2021; 103
References_xml – volume: 288
  start-page: 211
  year: 2018
  end-page: 217
  ident: b0105
  article-title: Toxicological investigation in blood samples from suspected impaired driving cases in the Milan area : Possible loss of evidence due to late blood sampling
  publication-title: Forensic Sci Int.
– reference: S. Saadat, Z.T. Rikhtegaran, L. James, N. Michelle, F. Matthew B., A.D. Harris, M.M. Sajadi, Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health CareWorkers Previously InfectedWith SARS-CoV-2, JAMA - J. Am. Med. Assoc. Mar 1;e213 (2021). doi:10.1001/jama.2021.3341.
– volume: 62
  start-page: 103101
  year: 2020
  ident: b0070
  article-title: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
  publication-title: EBioMedicine.
– volume: 56
  start-page: 1134
  year: 2000
  end-page: 1138
  ident: b0115
  article-title: A permutation test to compare receiver operating characteristic curves
  publication-title: Biometrics.
– reference: Worldometers, COVID-19 statistics.
– reference: F. Krammer, K. Srivastava, P. Team, V. Simon, H. Alshammary, A. Amoako, M. Awawda, K. Beach, C.M. 1 3 Bermúdez-González, D. Bialak, J.M. Carreño, R. Chernet, L. Eaker, E. Ferreri, D. Floda, C. Gleason, J. Hamburger, K. Jiang, G.D. Kleiner, J. Jurczyszak, W. Matthews, L. Mendez, I. Mulder, A. Nabeel, K. Raskin, A. Russo, M. Salimbangon, A. Saksena, G. Shin, L. Singh, D. Sominsky, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. 384 (2021) 1372-1374. doi: 10.1056/NEJMc2101667.
– volume: 39
  start-page: 4256
  year: 2021
  end-page: 4260
  ident: b0100
  article-title: Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects
  publication-title: Vaccine.
– volume: 12
  start-page: 431
  year: 2017
  end-page: 437
  ident: b0085
  article-title: Developing biological standards for vaccine evaluation
  publication-title: Future Virol.
– volume: 67
  start-page: 707
  year: 2021
  end-page: 709
  ident: b0060
  article-title: Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands
  publication-title: Clin. Chem.
– reference: C. Di Resta, D. Ferrari, M. Viganò, M. Moro, E. Sabetta, M. Minerva, A. Ambrosio, M. Locatelli, R. Tomaiuolo, The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects, Vaccines. May 18 (2021) 522. doi:10.3390/vaccines9050522.
– volume: 222
  start-page: 108634
  year: 2021
  ident: b0010
  article-title: COVID-19: A review of therapeutic strategies and vaccine candidates
  publication-title: Clin. Immunol.
– volume: 34
  start-page: 319
  year: 1997
  end-page: 320
  ident: b0110
  article-title: Method comparison: Evaluation of least squares, Deming and Passing/Bablok regression procedures using computer simulation
  publication-title: Ann. Clin. Biochem.
– reference: F. Muecksch, H. Wise, B. Batchelor, M. Squires, E. Semple, C. Richardson, J. McGuire, S. Clearly, E. Furrie, N. Greig, G. Hay, K. Templeton, J.C.C. Lorenzi, T. Hatziioannou, S. Jenks, P.D. Bieniasz, Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients, J. Infect. Dis. 223 (2020) 389–398. doi:10.1093/infdis/jiaa659.
– volume: 19
  start-page: 667
  year: 2020
  end-page: 668
  ident: b0015
  article-title: Evolution of the COVID-19 vaccine development landscape
  publication-title: Nat. Rev. Drug Discov.
– reference: C. Therrien, B. Serhir, M. Bélanger-Collard, J. Skrzypczak, D.K. Shank, C. Renaud, J. Girouard, V. Loungnarath, M. Carrier, G. Brochu, F. Tourangeau, B. Gilfix, A. Piche, R. Bazin, R. Guérin, M. Lavoie, V. Martel-Laferrière, C. Fortin, A. Benoit, D. Marcoux, N. Gauthier, A.M. Laumaea, R. Gasser, A. Finzi, M. Roger, Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories, J. Clin. Microbiol. 59 (2021). doi:10.1128/JCM.02511-20.
– reference: , 2008 (accessed 10 July 2021).
– reference: World Health Organization, WHO TRS: Recommendations for the preparation, characterization and establishment of international and other biological reference standards, http://www.who.int/immunization_standards/vaccine_reference_preparations/TRS932Annex 2_Inter _biol ef standards rev2004.pdf?ua=1, 2006 (accessed 12 March 2021).
– volume: 103
  start-page: 590
  year: 2021
  end-page: 596
  ident: b0050
  article-title: Clinical evaluation of commercial automated SARS-CoV-2 immunoassays
  publication-title: Int. J. Infect. Dis.
– reference: Centers for Disease Control and Prevention (US), SARS-CoV-2 Variants of Concern, Centers Dis. Control Prev. (2021). https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern%0Ahttps://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html. (accessed 12 June 2021).
– volume: 397
  start-page: 1057
  year: 2021
  end-page: 1058
  ident: b0030
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: Lancet
– reference: M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L. Lightstone, X.-N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, M. Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine., Lancet (London, England). 6736 (2021) 10–12. doi:10.1016/S0140-6736(21)00502-X.
– reference: WHO, Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody, 2020.
– reference: , 2020 (accessed 10 February 2021).
– volume: 49
  start-page: 1463
  year: 2021
  end-page: 1467
  ident: b0055
  article-title: Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
  publication-title: Clin. Chem. Lab. Med.
– volume: 129
  start-page: 104544
  year: 2020
  ident: b0065
  article-title: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests
  publication-title: J. Clin. Virol.
– volume: 56
  start-page: 1134
  year: 2000
  ident: 10.1016/j.cca.2021.08.024_b0115
  article-title: A permutation test to compare receiver operating characteristic curves
  publication-title: Biometrics.
  doi: 10.1111/j.0006-341X.2000.01134.x
– volume: 67
  start-page: 707
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0060
  article-title: Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands
  publication-title: Clin. Chem.
  doi: 10.1093/clinchem/hvab039
– ident: 10.1016/j.cca.2021.08.024_b0040
  doi: 10.3390/vaccines9050522
– volume: 129
  start-page: 104544
  year: 2020
  ident: 10.1016/j.cca.2021.08.024_b0065
  article-title: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests
  publication-title: J. Clin. Virol.
  doi: 10.1016/j.jcv.2020.104544
– ident: 10.1016/j.cca.2021.08.024_b0075
– ident: 10.1016/j.cca.2021.08.024_b0090
  doi: 10.1093/infdis/jiaa659
– volume: 288
  start-page: 211
  year: 2018
  ident: 10.1016/j.cca.2021.08.024_b0105
  article-title: Toxicological investigation in blood samples from suspected impaired driving cases in the Milan area : Possible loss of evidence due to late blood sampling
  publication-title: Forensic Sci Int.
  doi: 10.1016/j.forsciint.2018.04.038
– ident: 10.1016/j.cca.2021.08.024_b0095
– ident: 10.1016/j.cca.2021.08.024_b0035
  doi: 10.1001/jama.2021.3341
– volume: 12
  start-page: 431
  issue: 8
  year: 2017
  ident: 10.1016/j.cca.2021.08.024_b0085
  article-title: Developing biological standards for vaccine evaluation
  publication-title: Future Virol.
  doi: 10.2217/fvl-2017-0003
– volume: 39
  start-page: 4256
  issue: 31
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0100
  article-title: Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2021.06.020
– ident: 10.1016/j.cca.2021.08.024_b0025
  doi: 10.1016/S0140-6736(21)00502-X
– volume: 397
  start-page: 1057
  issue: 10279
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0030
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00501-8
– ident: 10.1016/j.cca.2021.08.024_b0020
  doi: 10.1056/NEJMc2101667
– volume: 49
  start-page: 1463
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0055
  article-title: Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
  publication-title: Clin. Chem. Lab. Med.
  doi: 10.1515/cclm-2021-0023
– ident: 10.1016/j.cca.2021.08.024_b0045
  doi: 10.1128/JCM.02511-20
– volume: 62
  start-page: 103101
  year: 2020
  ident: 10.1016/j.cca.2021.08.024_b0070
  article-title: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2020.103101
– volume: 103
  start-page: 590
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0050
  article-title: Clinical evaluation of commercial automated SARS-CoV-2 immunoassays
  publication-title: Int. J. Infect. Dis.
  doi: 10.1016/j.ijid.2020.12.003
– ident: 10.1016/j.cca.2021.08.024_b0005
– ident: 10.1016/j.cca.2021.08.024_b0080
– volume: 34
  start-page: 319
  issue: 3
  year: 1997
  ident: 10.1016/j.cca.2021.08.024_b0110
  article-title: Method comparison: Evaluation of least squares, Deming and Passing/Bablok regression procedures using computer simulation
  publication-title: Ann. Clin. Biochem.
  doi: 10.1177/000456329703400317
– volume: 222
  start-page: 108634
  year: 2021
  ident: 10.1016/j.cca.2021.08.024_b0010
  article-title: COVID-19: A review of therapeutic strategies and vaccine candidates
  publication-title: Clin. Immunol.
  doi: 10.1016/j.clim.2020.108634
– volume: 19
  start-page: 667
  issue: 10
  year: 2020
  ident: 10.1016/j.cca.2021.08.024_b0015
  article-title: Evolution of the COVID-19 vaccine development landscape
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/d41573-020-00151-8
SSID ssj0004061
Score 2.4883957
Snippet •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO...
Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS)...
SourceID pubmedcentral
proquest
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 144
SubjectTerms Comirnaty vaccine
COVID-19
Neutralization
SARS-CoV-2
Serological standard
WHO
Title Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects
URI https://dx.doi.org/10.1016/j.cca.2021.08.024
https://www.proquest.com/docview/2564131166
https://pubmed.ncbi.nlm.nih.gov/PMC8378065
Volume 522
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLZgSMAF8RTjpSBxQiq0WfrgOE2gAYIDL3GLkjaBIdQB3RBc-O3YawLsAAfUU5s6SmPHsRv7M8AOj1R8YOI8SFLLA4EuM-pBkQY2M4lBf6EQlhKFz86T7rU4uY1vJ6Djc2EorNLp_lqnj7S1e7LvZnP_qdejHN-Qih8SAhZKKs8mYYrjbp81YKp9fNo9_06PDJPIF1QjAn-4OQrzwi9AL5HXQJ5c_LY9_TA_x4Mnf-xGR_Mw58xI1q5HugATplyEmY6v3rYI02fu0HwJVFe9oLC5hEvWt6zqvbHnoSpHCWao7thl--Iy6PRvAs5QJL0-ZGhYq_eKUWz8HTUoIn5VOfaLJmrBqqGm3zjVMlwfHV51uoGrrBDk6G4MgjSOlNBJZNMkREZFoSUksVZm8Yojk2trbFGEwkQprt_CiuIgV8oqrdH84TpvrUCj7JdmFZjIcAVbdIsKa4UWucJOuY6JwhRxqpoQ-gmVuYMdp-oXj9LHlz1I5IEkHkiqiMlFE3a_SJ5qzI2_XhaeS3JMcCTuCX-RbXuOSuQMnZKo0vSHlUQbUBAGUZI0IR1j9ddgCJJ7vKXs3Y-guQmeH426tf8Nah1m6a5OddyAxuBlaDbR5hnoLZjc-4i2nGR_AvGgAss
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB5BkYDLiqe27AJG4oQUkbhO0h6riio82gMvcbPsxIaiVQqkRbv_fmcaG-gBDii3OBM5mcn4m3jmG4BDHqm4Y-I8SFLLA4EhM_pBkQa2bRKD8UIhLBUKD4ZJdiPO7uK7Bej5WhhKq3S-v_bpM2_tzhy7t3n8NBpRjW9IzQ-JAQstlbcXYUlQU-sGLHVPz7Phe3lkmES-oRoJ-M3NWZoXPgFGibwm8uTis-XpA_ycT578sBr11-CHg5GsW890HRZMuQErPd-9bQOWB27TfBNUpl7Q2FzBJRtbVo3-suepKmcFZuju2FX38irojW8DztAkvT9kCKzVv4pRbvw9DSgSflU53hchasGqqabfONUW3PRPrntZ4DorBDmGG5MgjSMldBLZNAlRUVFoiUms1bZ4xJHJtTW2KEJhohS_38KKopMrZZXWCH-4zlvb0CjHpfkJTLTxC7YYFhXWCi1yhTflOiYJU8SpakLoX6jMHe04db_4I31-2aNEHUjSgaSOmFw04ehN5Knm3PjqYuG1JOcMR-Ka8JXYgdeoRM3QLokqzXhaScSAgjiIkqQJ6Zyq3yZDlNzzI-XoYUbNTfT8COp2vjepfVjJrgcX8uJ0eP4LVmmkLnv8DY3Jy9TsIv6Z6D1n3_8BCjEEsQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Harmonization+of+six+quantitative+SARS-CoV-2+serological+assays+using+sera+of+vaccinated+subjects&rft.jtitle=Clinica+chimica+acta&rft.au=Ferrari%2C+Davide&rft.au=Clementi%2C+Nicola&rft.au=Span%C3%B2%2C+Sestina+Maria&rft.au=Albitar-Nehme%2C+Sami&rft.date=2021-11-01&rft.issn=1873-3492&rft.eissn=1873-3492&rft.volume=522&rft.spage=144&rft_id=info:doi/10.1016%2Fj.cca.2021.08.024&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon